Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab effects on eosinophil kinetics in eosinophilic asthma
NL-OMON26875Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Single-arm trial of mepolizumab in asthma and eosinophilic asthma (EA), sponsored by University Medical Center Utrecht. Primary endpoint: Change in eosinophil kinetics in sputum. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON26875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26875.